Soliqua™ 100/33 (insulin glargine/lixisenatide) – New drug approval
November 21, 2016 – Sanofi announced the FDA approval of Soliqua 100/33 (insulin glargine/lixisenatide) indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM inadequately controlled on basal insulin (< 60 units daily) or lixisenatide.
Top